Drug intelligence / Profile preview

BK1803

Development stage: Phase 3
Lead developer: Mitsubishi Tanabe Pharma
Modality: Vaccines & Immunotherapeutics
Administration: Intramuscular

Overview

**BK1803** is an investigational pediatric hexavalent combination vaccine developed by Tanabe Pharma for prevention of diphtheria, pertussis, tetanus, poliomyelitis, *Haemophilus influenzae* type b infection, and hepatitis B. It contains vaccine antigens directed against diphtheria, pertussis, tetanus, inactivated poliovirus, Hib, and hepatitis B, with the intended mechanism of inducing protective active immunity to each pathogen or toxin. BK1803 is being evaluated in a Phase 3 randomized, observer-blinded trial in healthy Japanese infants, using GOBIK plus Bimmugen as the active-control vaccination regimen.

Targets

Diphtheria toxinHBsAg (Hepatitis B surface antigen)PV3 (Sabin) (Poliovirus type 3 antigen)

Beyond the preview

Go deeper on BK1803.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BK1803.

Explore the full profile